AXSM vs CNS: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: CNS is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AXSM and CNS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AXSM and CNS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Axsome Therapeutics is a US-listed (Nasdaq: AXSM) central nervous system biopharmaceutical company built around approved products and a late-stage pipeline. Its flagship is Auvelity (dextromethorphan-bupropion), an oral NMDA-receptor modulator for major depressive disorder that has become the primary growth engine, plus Sunosi (solriamfetol) for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea, and Symbravo (meloxicam-rizatriptan) for acute migraine. The pipeline includes AXS-12 (reboxetine) filed with the FDA for cataplexy in narcolepsy, and earlier-stage assets such as AXS-20 (balipodect), a PDE10A inhibitor for schizophrenia and Tourette syndrome.

Full AXSM guide

Cohen & Steers is a global investment manager founded in 1986 that specializes in real assets and alternative income, including listed real estate (REITs), infrastructure, preferred securities, and multi-strategy real assets. It organized the first US real estate securities mutual fund and remains one of the largest managers of REIT securities in the world, with roughly two-thirds of assets in listed real estate. The firm earns management fees on the assets it runs across open-end funds, closed-end funds, institutional accounts, and newer vehicles like its non-traded REIT (CNSREIT).

Full CNS guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• AXSM drivers: Auvelity revenue ramp; Label and indication expansion.
• CNS drivers: Rate-cut tailwind for real assets; Return to organic growth.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Axsome remains unprofitable, reporting a Q1 2026 net loss of roughly $64.5M (about $1.26 per share), so the equity depends on future growth rather than current earnings. For CNS, cNS revenue is almost entirely tied to AUM, so equity or bond market drawdowns directly cut fees and earnings.

Pick AXSM if you believe its drivers more; CNS if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the AXSM and CNS guides.

AXSM. AXSM trades at a large-cap valuation despite still running net losses, so the multiple reflects expected growth and pipeline optionality rather than current profitability. The key figures to watch are Auvelity's quarterly sales trajectory and the path toward operating breakeven. Analysts broadly rate the stock favorably, but published targets vary widely and are not guarantees.

CNS. As of April 2026, CNS traded around a mid-20s price-to-earnings multiple with a dividend yield near 3.7%, reflecting its status as a profitable, dividend-paying specialty manager. Q1 2026 revenue of about $145.6 million grew roughly 8% year over year, and operating margin improved to about 34%. Because fees scale with AUM, valuation and earnings hinge on the direction of markets and flows into real-asset strategies.

Headline figures (approximate, JULY 2026): AXSM shows market cap ~$12.4B, revenue (q1 2026) ~$191M (up ~57% YoY), auvelity net sales (q1 2026) ~$153M (up ~59% YoY), sunosi net revenue (q1 2026) ~$34M (up ~34% YoY); CNS shows assets under management ~$93.1B, revenue (q1 2026) ~$145.6M, q1 2026 net inflows ~$497M, diluted eps (q1 2026) ~$0.82.

AXSM and CNS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined AXSM and CNS exposure against your real portfolio. It is not an investment adviser.